Cargando…

Ranking Self-reported Gastrointestinal Side Effects of Pharmacotherapy in Sarcoidosis

BACKGROUND: Clinical manifestations of sarcoidosis vary widely, depending on the intensity of the inflammation and the organ systems affected. So far, no curative treatment exists; the disease can only be suppressed. All treatment options cause side effects affecting quality of life. The aim of this...

Descripción completa

Detalles Bibliográficos
Autores principales:	Drent, M., Proesmans, V. L. J., Elfferich, M. D. P., Jessurun, N. T., de Jong, S. M. G., Ebner, N. M., Lewis, E. D. O., Bast, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Interstitial Lung Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105437/ https://www.ncbi.nlm.nih.gov/pubmed/31960165 http://dx.doi.org/10.1007/s00408-020-00323-8

Ejemplares similares

Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients
por: Proesmans, V. L. J., et al.
Publicado: (2019)

The Burden of Sarcoidosis Symptoms from a Patient Perspective
por: Voortman, M., et al.
Publicado: (2019)

Sarcoidosis and Work Participation: The Need to Develop a Disease-Specific Core Set for Assessment of Work Ability
por: Hendriks, C. M. R., et al.
Publicado: (2019)

Psychological burden associated with worse clinical outcomes in sarcoidosis
por: Sharp, Michelle, et al.
Publicado: (2019)

Physical Inactivity in Pulmonary Sarcoidosis
por: Cho, Peter S. P., et al.
Publicado: (2019)

Repository corticotropin for Chronic Pulmonary Sarcoidosis
por: Baughman, Robert P., et al.
Publicado: (2017)

Needs, Perceptions and Education in Sarcoidosis: A Live Interactive Survey of Patients and Partners
por: Moor, C. C., et al.
Publicado: (2018)

Sarcoidosis in the UK: insights from British Thoracic Society registry data
por: Thillai, Muhunthan, et al.
Publicado: (2019)

CASPA (CArdiac Sarcoidosis in PApworth) improving the diagnosis of cardiac involvement in patients with pulmonary sarcoidosis: protocol for a prospective observational cohort study
por: Quijano-Campos, Juan Carlos, et al.
Publicado: (2020)

Rationale and design of the SARCoidosis Outcomes in all respiratory Viral Infectious Diseases (SARCOVID) Study
por: Strykowski, Rachel, et al.
Publicado: (2022)

Yield of EBUS-TBNA for the diagnosis of sarcoidosis: impact of operator and cytopathologist experience
por: Navasakulpong, Asma, et al.
Publicado: (2016)

First patient-centred set of outcomes for pulmonary sarcoidosis: a multicentre initiative
por: Kampstra, Nynke A, et al.
Publicado: (2019)

Feasibility of investigating methylphenidate for the treatment of sarcoidosis-associated fatigue (the FaST-MP study): a double-blind, parallel-arm randomised feasibility trial
por: Atkins, Christopher, et al.
Publicado: (2021)

Effects of infliximab on lung and circulating natural killer cells, CD56+ T cells and B cells in sarcoidosis
por: Kullberg, Susanna, et al.
Publicado: (2021)

Mediators of systemic sclerosis-associated interstitial lung disease (SSc-ILD): systematic review and meta-analyses
por: Fields, Aislin, et al.
Publicado: (2023)

GLUT1-dependent glycolysis regulates exacerbation of fibrosis via AIM2 inflammasome activation
por: Cho, Soo Jung, et al.
Publicado: (2020)

Quantification of pulmonary perfusion in idiopathic pulmonary fibrosis with first pass dynamic contrast-enhanced perfusion MRI
por: Weatherley, Nicholas D, et al.
Publicado: (2021)

Central lung gene expression associates with myofibroblast features in idiopathic pulmonary fibrosis
por: Huang, Yong, et al.
Publicado: (2023)

Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA(1)) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)
por: Corte, Tamera J, et al.
Publicado: (2021)

Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF
por: Mercer, Paul F, et al.
Publicado: (2016)

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
por: Kolb, Martin, et al.
Publicado: (2017)

ILD-specific health-related quality of life in systemic sclerosis-associated ILD compared with IPF
por: Durheim, Michael T, et al.
Publicado: (2020)

Analytic Morphomics in Myositis-Related Interstitial Lung Disease
por: O’Mahony, Alexander T., et al.
Publicado: (2023)

Relationship between body composition, exercise capacity and health-related quality of life in idiopathic pulmonary fibrosis
por: Machado, Felipe V C, et al.
Publicado: (2021)

Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials
por: Lancaster, Lisa, et al.
Publicado: (2016)

Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects
por: Overed-Sayer, Catherine, et al.
Publicado: (2020)

Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry
por: Behr, Juergen, et al.
Publicado: (2014)

Incidence and prevalence of interstitial lung diseases worldwide: a systematic literature review
por: Shah Gupta, Rikisha, et al.
Publicado: (2023)

Responsiveness and meaningful change thresholds of the Living with Pulmonary Fibrosis (L-PF) questionnaire Dyspnoea and Cough scores in patients with progressive fibrosing interstitial lung diseases
por: Swigris, Jeffrey J, et al.
Publicado: (2022)

Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)
por: Maher, Toby M, et al.
Publicado: (2023)

Cryobiopsy versus open lung biopsy in the diagnosis of interstitial lung disease (COLDICE): protocol of a multicentre study
por: Troy, Lauren K, et al.
Publicado: (2019)

Sequencing of idiopathic pulmonary fibrosis-related genes reveals independent single gene associations
por: Coghlan, Meghan A, et al.
Publicado: (2014)

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis
por: Nathan, Steven D, et al.
Publicado: (2016)

Gene correlation network analysis to identify regulatory factors in idiopathic pulmonary fibrosis
por: McDonough, John E, et al.
Publicado: (2019)

‘It’s difficult, it’s life changing what happens to you’ patient perspective on life with chronic hypersensitivity pneumonitis: a qualitative study
por: Aronson, Kerri I, et al.
Publicado: (2019)

Derivation and validation of a simple multidimensional index incorporating exercise capacity parameters for survival prediction in idiopathic pulmonary fibrosis
por: Chandel, Abhimanyu, et al.
Publicado: (2023)

Rationale for and design of the Idiopathic Pulmonary Fibrosis–PRospective Outcomes (IPF-PRO) registry
por: O'Brien, Emily C, et al.
Publicado: (2016)

Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis
por: Kreuter, Michael, et al.
Publicado: (2017)

Cluster analysis of transcriptomic datasets to identify endotypes of idiopathic pulmonary fibrosis
por: Kraven, Luke M, et al.
Publicado: (2023)

Growth Hormone-Releasing Hormone Receptor Antagonist Modulates Lung Inflammation and Fibrosis due to Bleomycin
por: Zhang, Chongxu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0hjhb2rre3fcb7bl7p2ccrqa1k